Curcumin synergistically enhances the radiosensitivity of human oral squamous cell carcinoma via suppression of radiation-induced NF-κB activity

I-TSANG CHIANG1*, YU-CHANG LIU1,2*, FEI-TING HSU1*, YI-CHUN CHIEN1,3, CHIH-HAO K. KAO4, WUU-JYH LIN5, JING-GUNG CHUNG6 and JENG-JONG HWANG1

1Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei; 2Department of Radiation Oncology, National Yang-Ming University Hospital, Yilan; 3Department of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung; 4Department of Radiopharmaceutical Production, Hualien Tzu Chi Hospital, Hualien; 5Division of Radioisotope, Institute of Nuclear Energy Research, Taoyuan; 6Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.

Received September 16, 2013; Accepted November 11, 2013

DOI: 10.3892/or.2014.3009

Abstract. The anticancer effect of curcumin has been widely reported. However, whether curcumin can enhance the radiosensitivity of human oral squamous cell carcinoma (OSCC) remains to be elucidated. The aim of the present study was to evaluate the efficacy of curcumin combined with radiation against OSCC. SAS cells were transfected with the luciferase gene (luc) and named SAS/luc. NF-κB/DNA binding activity, the surviving fraction and NF-κB-regulated effector protein expression were determined by electrophoretic mobility shift assay, clonogenic survival assay and western blotting, respectively. The therapeutic efficacy was evaluated in SAS/luc tumor-bearing mice by caliper measurement and bioluminescence imaging. Curcumin enhanced SAS/luc radiosensitivity through the inhibition of radiation-induced NF-κB activity and expression of effector proteins both in vitro and in vivo. With 4 Gy or greater radiation doses, synergistic effects of curcumin were observed. The combination group (curcumin plus radiation) had significantly better tumor control compared with that of curcumin or radiation alone. No significant body weight change of mice was found throughout the entire study. In conclusion, curcumin is a radiosensitizer against OSCC with negligible toxicity.

Introduction

Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer in Taiwan. Radiotherapy plays a major role in the postoperative or definitive treatment for patients with locoregionally advanced disease. Unfortunately, more than half of high-risk patients develop locoregional recurrence and/or distant metastasis despite aggressive treatment (1). Radioresistance has been described in the literature to be related to several signaling pathways, such as cyclooxygenase-2 (COX-2), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-α (TNF-α) and hypoxia-inducible factor-α (HIF-α) (2-4). Nuclear factor-κB (NF-κB) is the key molecule for relaying signals from these pathways to express downstream effectors, which are responsible for radioresistance (2).

Irradiation is able to activate NF-κB and subsequent transcription of effector proteins governing cell proliferation (such as cyclin D1), angiogenesis [such as vascular endothelial growth factor (VEGF)], invasion (such as MMP-9), and anti-apoptosis [such as B-cell lymphoma 2 protein (BCL-2), x-linked inhibitor of apoptosis protein (XIAP) and cellular FLICE-like inhibitory protein (C-FLIP)], resulting in radioresistance and poorer treatment outcome (5,6). These NF-κB-regulated effectors (i.e. cyclin D1, VEGF, MMP-9, BCL-2 and XIAP) have...
been suggested to be biomarkers indicating cancer treatment resistance in OSCC (7-10).

Inhibition of the NF-κB signaling cascade increases cancer cell sensitivity to radiotherapy and chemotherapy (11,12). In addition, tumor infiltrating inflammatory and stromal cells in the microenvironment promote prosurvival and oncogenic signals through activation of NF-κB, which appears to be an appropriate target for cancer therapy from the aspect of reversing therapeutic resistance (6).

In comparison with radiotherapy alone, combined chemotherapy and radiotherapy (CCRT) simultaneously could enhance locoregional control and disease-free survival in patients with high-risk head and neck cancer. However, acute severe toxicity occurs more frequently in patients receiving CCRT and may affect treatment compliance and even result in treatment-related death (13). An ideal radiosensitizer should enhance the radiosensitivity of cancer cells to achieve better tumor control without increasing normal tissue toxicity. Curcumin, commonly known as the spice turmeric, is a polyphenol derived from the plant Curcuma longa, and has been shown to have anticancer, antioxidant and anti-inflammatory effects (14). When embedded with liposome and administered intravenously, curcumin is able to reduce radiation-induced lung damage (15). Treating OSCC with curcumin was found to result in growth inhibition through suppression of NF-κB (16). Radiation combined with curcumin was found to have an additive effect on head and neck squamous cell carcinoma possibly through inhibition of epidermal growth factor receptor (EGFR) phosphorylation and COX-2 expression (17). Nevertheless, whether curcumin can sensitize OSCC to radiation via suppression of NF-κB activation has not yet been elucidated. In the present study, we used molecular imaging to evaluate the therapeutic efficacy of curcumin combined with radiation on luciferase reporter gene (luc)-carrying OSCC cell line (SAS/luc) tumor-bearing mice. The effect of curcumin on radiation-induced NF-κB activity and NF-κB-regulated products in SAS/luc cells was also investigated. In order to verify the role of NF-κB inhibition, SAS cells were transfected with NF-κB super-repressor (p-IκBαM). The combined effects of p-IκBαM transfection and radiation on SAS cells were studied.

**Materials and methods**

**Experimental design.** The *in vitro* and *in vivo* studies were divided into two parts. The first part was to investigate whether curcumin has a radiosensitizing effect and the experiments were subdivided into four groups: the control group (control or vehicle), curcumin-treated group (curcumin alone), radiation-treated group (radiation alone) and combined treatment group (combination). The other part was to verify the effect of the IκBαM vector, which represses constitutive or radiation-induced NF-κB activity, to radiosensitize the OSCC cell line. This experiment was also subdivided into four groups: empty vector-transfected group (empty vector), p-IκBαM-transfected group (IκBαM vector), radiation-treated group (radiation alone) and p-IκBαM-transfection plus radiation group (combination). The Experimental Animal Care and Use Committee of the National Yang-Ming University Office of Research and Development approved the experiment.

Plasmid transfection and stable clone selection. Stable clones of SAS/luc cells were established as described in our previous study (18). In brief, SAS cells were transfected with the pCI-luc vector using jetPEI™ (Polyplus Transfection, Sélestat, France). Cells (2×10⁶) were seeded in a 100-mm diameter dish containing 3 ml Dulbecco’s modified essential medium (DMEM; Gibco-Life Technologies, Grand Island, NY, USA) 24 h before transfection. pCI1-luc (5 µl) and 10 µl of jetPEI™ solution were diluted in 500 µl of 150 mM NaCl, respectively, then mixed together and incubated for 30 min at 37°C. The jetPEI/plasmid vector mixture was added to SAS cells and incubated at 37°C for another 24 h. Cells were then trypsinized and cultured in 100-mm dishes with DMEM containing 1 mg/ml G418 (Merek, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; Biological Industries, Beit Haemek, Israel) for 2 weeks. The surviving clones were isolated and transferred to 96-well plates for growth. The Luc protein expression in each clone was assayed using BLI. The recombinant bioluminescent cell clone was named SAS/luc.

The IκBα mutant vector (p-IκBαM; Clontech, Mountain View, CA, USA) was used to transfect SAS cells using the same protocol as in our previous study (19). The inhibitory effect of p-IκBαM super repressor on NF-κB activation was confirmed with electrophoretic mobility shift assay (EMSA). p-IκBαM-transfected SAS cells were used as a negative control of NF-κB activation.

**Cell culture.** SAS/luc cells were cultured in DMEM supplemented with 10% FBS and 100 µg/ml streptomycin (Gibco-Life Technologies) at 37°C in a humidified atmosphere of 5% CO₂. G418 (500 µg/ml) was added to the medium to maintain the stable expression of the luc gene.

Cytotoxicity of curcumin. SAS/luc cells were seeded in 96-well plates (3,000 cells/well), incubated for 24 h, and then treated with different concentrations (0-50 µM) of curcumin (Sigma-Aldrich, St. Louis, MO, USA) for another 24 or 48 h. Cells were then washed with fresh medium. Subsequently, 100 µl of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution was added into each well and incubated for 4 h at 37°C. After removing the MTT solution, cells were exposed to 100 µl of dimethyl sulfoxide for 5 min, and plates were scanned with an enzyme-linked immuno-sorbent assay (ELISA) reader (PowerWave X340; BioTek, Winooski, VT, USA) using a test wavelength of 570 nm and a reference wavelength of 630 nm.

**Clonogenic survival assay.** SAS/luc cells (1×10⁶) were seeded in 100-mm dishes (2 dishes per group), incubated for 24 h, and then treated with or without 30 µM curcumin (i.e. half maximal inhibitory concentration, IC₅₀). Cells were irradiated immediately with various doses (2-12 Gy) using an X-ray irradiator (RS 2000; Rad Source Technologies, Suwanee, GA, USA) at a dose rate of 1.03 Gy/min, 80 cm source-to-skin distance (SSD) and field size of 30x30 cm². After irradiation, cells were incubated for 24 h. After that, cells were trypsinized, washed and resuspended in fresh medium, and then seeded in 100-mm diameter dishes. Twelve days later, the cell colonies were fixed with methanol:acetic acid (3:1) solution and stained with 2% crystal violet. The cell colony was deemed surviving when
there were >50 cells. The surviving fraction (SF) was defined as the ratio of surviving colonies to the number of plated cells with correction for plating efficiency. The radiosensitization effect of curcumin on SAS/luc cells was evaluated according to the formulas (as listed below) suggested by Valeriote and Lin (20) and Carpentier et al (21).

- Synergism, $SF_{R+C} < SF_R \times SF_C$
- Additivity, $SF_{R+C} = SF_R \times SF_C$
- Sub-additivity, $SF_{R+C} > SF_R \times SF_C$, with $SF_{R+C} < SF_R$ and $SF_{R+C} < SF_C$
- Antagonism, $SF_{R+C} > SF_R$ and/or $SF_{R+C} > SF_C$

where $SF_R$ is the surviving fraction of SAS/luc cells treated by radiation alone; $SF_C$ is the surviving fraction of SAS/luc cells treated with IC$_{50}$ curcumin alone ($SF_C = 0.5$); $SF_{R+C}$ is the surviving fraction of SAS/luc cells treated by radiation plus IC$_{50}$ curcumin.

The surviving fraction of SAS/luc cells transfected with the empty or p-IkBxM vector was obtained using the same procedure as mentioned above.

Electrophoretic mobility shift assay (EMSA). After treatment with 6 Gy irradiation, 30 µM curcumin for 24 h, or a combination of both, a nuclear extraction kit (Chemicon, EMD Millipore, Billerica, MA, USA) was used to isolate the nuclear fractions of SAS/luc cells. The protocol for NF-xB/DNA binding activity evaluation followed the instructions provided with the kit (LightShift Chemiluminescent EMSA kit; Thermo Scientific Pierce Protein Biology Products, Rockford, IL, USA). The following DNA sequences were synthesized for EMSA analysis: sense, AGTTGAGGGGACTTTCCCAGGC and antisense, GCCTGGAAAGTCCCTCACT. Nuclear extracts were incubated with the biotin-labeled DNA probe for 20 min at room temperature. The DNA-protein complex was separated from the free oligonucleotides on a 5% polyacrylamide gel, transferred to a nylon membrane and cross-linked by UV light. The membrane was incubated with streptavidin-horseradish peroxidase and detected by enhanced chemiluminescence (ECL; Thermo Scientific Pierce Protein Biology Products).

DNA fragmentation. SAS/luc cells (1x10^6) were grown in 6-well plates and treated with 6 Gy irradiation, 30 µM curcumin for 24 h or a combination of both. After treatment, a genomic DNA purification kit (Axygen, Tewksbury, MA, USA) was used to extract fragmented DNA following the protocol provided by the manufacturer. DNA laddering was analyzed with 1.5% agarose gel electrophoresis.

Western blotting. SAS/luc cells (2x10^6) were seeded into 100-mm diameter dishes and treated with 30 µM curcumin, 6 Gy irradiation or a combination of both. The cells were then lysed with 100 µl lysis buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% NP-40, 1 mM phenylmethanesulfonyl fluoride). Total proteins (40 µg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride membrane (EMD Millipore). The membranes were blocked with 5% non-fat milk for 1 h, and probed with the appropriate primary antibody (VEGF, MMP-9, BCL-2, XIAP, C-FLIP, cleaved-caspase-3, caspase-8, cytochrome c and β-actin; EMD Millipore) overnight at 4°C. The membranes were then washed in Tris-Tween buffer saline and incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) at room temperature for 1 h. Final quantification was achieved by using an ECL detection system (EMD Millipore). A cytosol/nuclear extraction kit (Chemicon International, Temecula, CA, USA) was used to isolate cytosolic cytochrome c following the instructions provided with the kit (22).

Tumor-bearing animal model. Six-week-old male NOD/SCID mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan. SAS/luc cells (1x10^6) in 0.2 ml serum-free medium were inoculated subcutaneously into the right legs of NOD/SCID mice. When the tumor volume reached 70 mm³, mice were randomized into four groups (n=5 for each group) according to the treatment modality: i) control group (phosphate-buffered solution with 1% dimethyl sulfoxide by gavage daily); ii) curcumin alone group (70 mg/kg/day by gavage from day 1 for 3 weeks); iii) radiation alone group (single dose 6 Gy on day 1); and iv) combination group (70 mg/kg/day by gavage from day 1 for 3 weeks plus 6 Gy irradiation on day 1). The treatment protocol for mice is depicted in Fig. 4. Tumor volume was measured by caliper weekly and calculated by the following formula (23): Volume = 1/2 x (4/3)π x length/2 x width/2 x thickness = 0.523 x (length x width x thickness).

The body weight of mice was monitored after treatment together with tumor volume tracking. Mice were sacrificed on day 21 for pathologic examination of the liver. All animal experiments complied with institutional animal care guidelines.

In vivo bioluminescent imaging (BLI). SAS/luc tumor-bearing mice received 150 mg/kg D-luciferin injection intraperitoneally. Before imaging, mice were anesthetized using 1-3% isoflurane for 15 min and continuously exposed to 1-2% isoflurane to maintain a sedative state during imaging. The photons emitted from the tumors were detected in vivo by IVIS 50 Imaging system (Xenogen Corp., Alameda, CA, USA). Image acquisition time was 10 sec. Regions of interest (ROIs) were drawn around the tumor and quantified as photons/second (p/sec) using Living Image software (Xenogen). In vivo BLI was performed once a week for three weeks, and the serial bioluminescent signals were quantified and displayed over time.

Ex vivo EMSA. Mice were sacrificed on day 21 of the treatment period, and tumors were removed for nuclear protein extraction by using a nuclear extraction kit. The NF-xB/DNA binding activity was evaluated using LightShift Chemiluminescent EMSA kit.

Ex vivo western blotting. Mice were sacrificed on day 21 of the treatment period and tumors were removed for protein extraction using the T-PER kit (Thermo Scientific Pierce Protein Biology Products). Equal amounts of protein (40 µg) were loaded on SDS-PAGE for electrophoresis and then transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies specific for VEGF, MMP-9, BCL-2, XIAP, C-FLIP, cleaved caspase-3, caspase-8, cytochrome c.
and β-actin, followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Protein expression was determined by ECL. All reagents and antibodies were purchased from EMD Millipore, except XIAP, which was purchased from Abcam (Cambridge, UK).

Statistical analysis. Data are presented as means ± standard deviation (SD). Student’s t-test was used for analysis, and P<0.05 was considered to indicate a statistically significant result.

Results

Curcumin induces apoptosis and suppresses NF-κB-mediated tumor progression-related proteins in SAS/luc cells in a time-dependent manner. Fig. 1A shows that curcumin killed more SAS/luc cells, as depicted by decreased cell viability, with increasing concentrations (10-50 µM) and longer treatment time (48 h). The IC<sub>50</sub> for curcumin was about 30 µM, which was selected for subsequent experiments. DNA laddering, which represents cell apoptosis, became more obvious in the SAS/luc cells when the cells were treated with curcumin for 48 h as compared to that at 24 h (Fig. 1B). Curcumin suppressed NF-κB/DNA binding activity also in a time-dependent manner (Fig. 1C). Expression of apoptotic proteins (i.e. cleaved caspase-3, cleaved caspase-8 and cytochrome c) increased while NF-κB-regulated effector proteins (i.e. angiogenesis protein VEGF, invasion protein MMP-9 and anti-apoptosis proteins BCL-2, XIAP and C-FLIP) decreased with curcumin treatment (Fig. 1D), both in a time-dependent manner.

Transfection of p-IκBαM suppresses radiation-induced NF-κB activity and sensitizes SAS/luc cells to radiation. SAS cells were transfected with p-IκBαM, a super-repressor of NF-κB, as a negative control of NF-κB activation. The radiation-induced NF-κB/DNA binding activity was inhibited by p-IκBαM (Fig. 2A). Transfection of p-IκBαM significantly

Figure 1. Curcumin inhibits tumor progression of SAS/luc cells in a time-dependent manner. (A) The SAS/luc cells were treated with 0-50 µM curcumin for 24 or 48 h. The cell viability was evaluated using an MTT assay. (B) Curcumin induced DNA fragmentation. (C) The result of EMSA indicated that the NF-κB/DNA binding activity was suppressed by curcumin. (D) Western blotting revealed changes in the level of apoptotic-related and NF-κB-regulated proteins after curcumin treatment. β-actin was used as an internal control. Representative data from three independent experiments are shown. **P<0.01.
increased radiation cytotoxicity at all doses (2-12 Gy) as compared with the transfection of the empty vector (Fig. 2B). Radiation-induced apoptosis, represented by DNA fragmentation (Fig. 2C) or increased apoptosis-related protein levels (Fig. 2D), was also enhanced following the transfection of p-IκBαM. Finally, the expression of radiation-induced NF-κB-regulated protein expression and increased radiation-induced apoptosis-related protein expression. Protein expression was assayed by western blotting. Representative data from three independent experiments are shown. \(^{**}P<0.01\) as compared with the empty vector. Ctr, empty vector; IκBαM, IκBαM vector; R, radiation alone; Comb, combination.

**Curcumin suppresses radiation-induced NF-κB activity and synergistically sensitizes SAS/luc cells to radiation.** Curcumin inhibited radiation-induced NF-κB/DNA binding activity (Fig. 3A). The combination of curcumin with radiation significantly decreased the survival fraction at all doses (2-12 Gy) when compared with the radiation alone group (Fig. 3B). Synergistic effects were noticed with radiation doses >2 Gy (Table I). In addition, curcumin increased radiation-induced apoptosis as shown by DNA fragmentation (Fig. 3C) and increased apoptotic proteins levels (i.e. cleaved caspase-3, cleaved caspase-8 and cytochrome c in Fig. 3D). Fig. 3D indicates that curcumin suppressed radiation-induced NF-κB

---

### Table I. Effect of 30 µM curcumin combined with various doses of radiation on SAS/luc cells.

<table>
<thead>
<tr>
<th>Radiation (Gy)</th>
<th>SF&lt;sub&gt;R&lt;/sub&gt;</th>
<th>SF&lt;sub&gt;R+C&lt;/sub&gt;</th>
<th>SF&lt;sub&gt;R x SF&lt;/sub&gt;C</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.56</td>
<td>0.37 (sub-additivity)</td>
<td>0.28</td>
</tr>
<tr>
<td>4</td>
<td>0.42</td>
<td>0.13 (synergism)</td>
<td>0.21</td>
</tr>
<tr>
<td>6</td>
<td>0.22</td>
<td>0.05 (synergism)</td>
<td>0.11</td>
</tr>
<tr>
<td>8</td>
<td>0.08</td>
<td>0.01 (synergism)</td>
<td>0.04</td>
</tr>
<tr>
<td>10</td>
<td>0.03</td>
<td>0.003 (synergism)</td>
<td>0.01</td>
</tr>
<tr>
<td>12</td>
<td>0.01</td>
<td>0.0005 (synergism)</td>
<td>0.00</td>
</tr>
</tbody>
</table>
Figure 3. Curcumin sensitizes SAS/luc cells to radiation. (A) Radiation-induced NF-κB activity was inhibited by curcumin treatment. The NF-κB/DNA binding activity was evaluated with EMSA. (B) Curcumin significantly increased radiation-induced cytotoxicity. SAS/luc cells were treated with or without 30 μM curcumin followed by immediate irradiation with various doses (see context for detail). The surviving fraction was determined with clonogenic survival assay. (C) Curcumin increased radiation-induced DNA fragmentation. (D) Curcumin decreased radiation-induced NF-κB-regulated protein expression and increased radiation-induced apoptosis-related protein expression. Protein expression was assayed by western blotting. (Representative data from three independent experiments are shown. **P<0.01 as compared with radiation alone. Ctr, control; Cur, curcumin alone; R, radiation alone; Comb, combination.

Figure 4. Schematic depiction of the experimental design. SAS/luc tumor-bearing mice were divided into four groups: vehicle-treated control group; radiation-treated (single 6 Gy on day 1) group; curcumin-treated (70 mg/kg/day by gavage from day 1) group; and combined treatment (curcumin plus radiation) group.}

**Image**: Schematic depiction of the experimental design. SAS/luc tumor-bearing mice were divided into four groups: vehicle-treated control group; radiation-treated (single 6 Gy on day 1) group; curcumin-treated (70 mg/kg/day by gavage from day 1) group; and combined treatment (curcumin plus radiation) group.
downstream effector protein expression (i.e. VEGF, MMP-9, BCL-2, XIAP and C-FLIP). These findings were identical to those observed in the aforementioned p-IκBαM-transfected group.

**Curcumin enhances the therapeutic efficacy of radiation in the SAS/luc tumor-bearing mice.** Fig. 4 depicts a flow chart of the *in vivo* experiment. SAS/luc tumor-bearing mice were divided into four groups: the vehicle-treated control (vehicle) group, the curcumin-treated (curcumin alone) group, the radiation-treated (radiation alone) group, and the combined treatment (combination) group. Mice were treated according to the grouping when the tumor volume reached $70 \text{ mm}^3$. Fig. 5A depicts the tumor growth curve measured by caliper during the experiment. All the treatment groups showed significantly enhanced inhibition of tumor growth when compared with the control. *P*<0.05, **P**<0.01 as compared with the control. *P*<0.05, ***P***<0.01 as compared with the other treatment groups.
control group. The combined treatment group (combination) exhibited optimal tumor control and a significantly smaller tumor volume on day 21 in comparison with the curcumin-treated (curcumin alone) or radiation-treated (radiation alone) group. BLI was also used to evaluate the therapeutic efficacy. On day 21 as shown in Fig. 5B and C, photons emitted from the tumors of the treatment groups were significantly lower than photons from the tumors of the control group. Photon flux of the combination group was significantly lower when compared with the photon flux in the curcumin or radiation alone group. As predicted in the in vitro data, ex vivo EMSA and western blotting showed that curcumin inhibited radiation-induced NF-κB/DNA binding activity, increased radiation-induced apoptotic protein levels, and suppressed radiation-induced NF-κB downstream effector protein expression (Fig. 5D and E). We traced body weight changes of the mice to evaluate the potential toxicity caused by the treatments. There were no significant changes (i.e. within 20% of the original weight) observed in all four groups (Fig. 6A). Pathological examination showed no difference in the mouse liver morphology among all the groups (Fig. 6B).

**Discussion**

Radiotherapy- or chemotherapy-induced NF-κB activity has been reported in numerous studies and is closely correlated with radioresistance or chemoresistance (5). Inappropriate NF-κB activation results in malignant behavior and anti-apoptotic activity of OSCC (24,25). In clinical practice, it was found that overexpression of NF-κB is highly correlated with poor treatment outcome (26). We previously showed that curcumin inhibits the proliferation of human OSCC both in vitro and in vivo by inducing apoptosis (18). However, inhibition of NF-κB activation does not always result in enhanced radiosensitivity. Instead, radiosensitization is a cell type-specific phenomenon following NF-κB suppression (27). The transfection of p-IkBαM, a super repressor of NF-κB, inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced NF-κB activity (19) and increases radiation-induced cytotoxicity in breast cancer (28). We found that the radiation-induced NF-κB/DNA binding activity and NF-κB-regulated effector protein expression were inhibited by p-IκBαM (Fig. 2A and D). In addition, p-IκBαM enhanced radiation-induced cytotoxicity and apoptosis via the mitochondrial-dependent and -independent pathways as shown in Fig. 2B-D. These results together suggest that inhibition of radiation-induced NF-κB activity is able to sensitize SAS cells to radiation (Fig. 2).

Several methods have been suggested to suppress NF-κB activation and various synthetic drugs or natural compounds are used to inhibit radiation-induced NF-κB activity (29,30). Natural compounds are preferred in clinical practice due to low cytotoxicity and multiple mechanisms of action (14,31). Curcumin is a natural compound capable of decreasing cell survival, invasion, and angiogenesis via NF-κB signal cascade suppression in several types of cancers (31,32). Our experimental results on the OSCC cell line SAS/luc showed that curcumin inhibited cell proliferation (Fig. 1A), constitutive NF-κB/DNA binding activity (Fig. 1C) and NF-κB downstream effector protein expression (Fig. 1D) while it induced apoptosis via the mitochondrial-dependent and -independent pathways (Fig. 1B and D). Furthermore, curcumin inhibited radiation-induced NF-κB/DNA binding activity (Fig. 3A) and NF-κB-regulated effector protein expression (Fig. 3D) in addition to enhancing radiation cytotoxicity (Fig. 3B) and apoptosis (Fig. 3C and D). When compared with the surviving fraction of the radiation alone group, the combination group showed the synergistic effect (Table I) of curcumin. All these findings indicate that curcumin sensitizes SAS cells to radiation in vitro, similar to that observed in p-IκBαM-transfected cells, via inhibition of radiation-induced NF-κB activity.

Fig. 5A-C shows that curcumin enhanced the antitumor effect of radiation in SAS/luc cells in vivo through suppression of radiation-induced NF-κB/DNA binding activity (Fig. 5D) and NF-κB-regulated effector protein expression (Fig. 5E). The body weight changes of all the mice throughout the entire experiment were within 20% of the original weight (Fig. 6A). In addition, no evidence of liver parenchymal injury.
or morphologic change was found by pathological examination. Both results indicated that there was no marked toxicity of curcumin treatment. No toxicity has been reported for curcumin at a single dose of 12 g/day by oral administration in a clinical trial (33). Thus, curcumin may be an ideal radiosensitizer for future clinical use because of its radiosensitizing effect and extremely low toxicity.

In conclusion, the present study demonstrated that curcumin sensitizes human OSCC to radiation via inhibition of radiation-induced NF-κB activity. Combination of curcumin with radiation exerts a synergistic effect in vitro and enhances tumor control in vivo without noticeable toxicity.

Acknowledgements

The present study was supported by grants NSC 97-2314-B-010-045-MY3 and NSC 97-2314-B-010-046-MY3 from the National Science Council, Taipei, Taiwan. The imaging facility was supported by the Taiwan Mouse Clinic.

References